There have been attempts to introduce the targeted therapy into the management of resistant TGCT (such as small molecular inhibitors—e.g., imatinib, an inhibitor of the KIT/KITL signaling pathway; or monoclonal antibodies—e.g., bevacizumab, an inhibitor of VEGF (vascular endothelial growth factor), angiogenesis, and tumor growth, recently also immune check-point inhibitors), but the results of these studies were unsatisfactory [20,21,22,23,24]. Here, VEGFA is linked to neoplasm.